A federal judge determined that Johnson & Johnson will have another opportunity to contest the scientific evidence linking talc products ovarian cancer, Reuters’ Dietrich Knauth reports. The move could potentially disrupt a federal court case that consolidates 53,000 talc-based lawsuits, the author notes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ: